Home·Stocks·RVMD

RVMD

Nasdaq

Revolution Medicines, Inc.

Basic Materials · Biological Products, (No Diagnostic Substances)

Research view

Fundamentals · SEC EDGAR · FY 2025-12-31

Revenue & Earnings — fiscal year

$29.4M

2021

$35.4M

2022

$11.6M

2023

2024

2025

Snapshot

SEC EDGAR · FY 2025-12-31

Revenue$0

Net Income—

Gross Profit—

Oper Income$-1.2B

EPS (dil)$-5.95

Rev/sh$0.00

FCF/sh$-4.30

Book/sh$7.67

Gross M—

Oper M—

Profit M—

FCF M—

ROE—

ROA—

ROIC-95.1%

R&D/Rev—

Rev Y/Y—

Rev 3Y CAGR-100.0%

EPS Y/Y-66.2%

EPS 3Y CAGR—

FCF 3Y CAGR—

Payout—

Div/sh—

Shs Chg Y/Y+13.3%

Current Ratio7.14

Quick Ratio—

Debt/Eq—

Int Coverage-48.8×

Net Debt—

Total Debt—

Cash & Eq$388.6M

Total Assets$2.4B

Oper CF$-897.7M

Capex$16.0M

Free CF$-913.7M

Buybacks—

Equity$1.6B

Liabilities$723.2M

Shs Outstand0.21B

SectorBasic Materials

🔒 P/E—

🔒 Fwd P/E—

🔒 P/S—

🔒 P/B—

🔒 Market Cap—

🔒 Div Yield—

🔒 52W Range—

🔒 Beta—

40+ fundamentals — free from SEC EDGAR (public domain). Only the 🔒 price-derived column needs a market-data feed.

Financials — annual

SEC EDGAR · last 5 FY

USD	FY2021	FY2022	FY2023	FY2024	FY2025
Revenue	$29.4M	$35.4M	$11.6M	$0	$0
Gross Profit	—	—	—	—	—
Operating Income	$-188.0M	$-258.3M	$-487.2M	$-689.5M	$-1.2B
Net Income	$-187.1M	$-248.7M	$-436.4M	$-600.1M	$-1.1B
Diluted EPS	$-2.57	$-3.08	$-3.86	$-3.58	$-5.95
Operating Cash Flow	$-147.2M	$-224.4M	$-350.6M	$-557.4M	$-897.7M
Free Cash Flow	$-153.7M	$-235.2M	$-358.3M	$-567.7M	$-913.7M

COMMUNITY · $RVMD0 theses

POST YOUR TAKE →

Ask AI about RVMD Build basket with RVMD Screener

Fundamentals sourced from SEC EDGAR filings (public domain). For informational purposes only. Not investment advice.